At six weeks, repeat the metabolic panel and lipid panel
The cells were exposed to a range of treatments: TGF-1 (10 ng/ml, R&D Systems Inc., Minneapolis, USA), IL-1 (10 ng/ml, R&D Systems Inc., Minneapolis, USA), MCC950 (10 M, Selleck, Houston, TX, USA), 3PO (10 or 30 M, Selleck, Houston, TX, USA), liraglutide (10, 100 or 1000 nM, Selleck, Houston, TX, USA), and sodium L-lactate (20 mM, Sigma-Aldrich, St
Paragraph IV certification (if filing before patent expiration): If the generic manufacturer believes Novo Nordisk's patents are invalid or not infringed, it can file a Paragraph IV certification
Some wont yet the research is moving faster than the textbooks